NO20073033L - Cytotoksiske midler innbefattende nye taksaner - Google Patents

Cytotoksiske midler innbefattende nye taksaner

Info

Publication number
NO20073033L
NO20073033L NO20073033A NO20073033A NO20073033L NO 20073033 L NO20073033 L NO 20073033L NO 20073033 A NO20073033 A NO 20073033A NO 20073033 A NO20073033 A NO 20073033A NO 20073033 L NO20073033 L NO 20073033L
Authority
NO
Norway
Prior art keywords
cytotoxic agents
taxanes
agents including
including new
new taxanes
Prior art date
Application number
NO20073033A
Other languages
English (en)
Norwegian (no)
Inventor
Alain Commercon
Michael Miller
Ravi V J Chari
Erkan Baloglu
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073033(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20073033L publication Critical patent/NO20073033L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20073033A 2004-12-07 2007-06-14 Cytotoksiske midler innbefattende nye taksaner NO20073033L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292898A EP1669358A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new taxanes
PCT/EP2005/014177 WO2006061258A2 (en) 2004-12-07 2005-12-02 Cytotoxic agents comprising new taxanes

Publications (1)

Publication Number Publication Date
NO20073033L true NO20073033L (no) 2007-08-28

Family

ID=34931583

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073033A NO20073033L (no) 2004-12-07 2007-06-14 Cytotoksiske midler innbefattende nye taksaner

Country Status (22)

Country Link
US (1) US7667054B2 (es)
EP (2) EP1669358A1 (es)
JP (1) JP2008523019A (es)
KR (1) KR20070085781A (es)
CN (1) CN101094857A (es)
AR (1) AR054100A1 (es)
AU (1) AU2005313444B2 (es)
BR (1) BRPI0518869A2 (es)
CA (1) CA2588587A1 (es)
DO (1) DOP2005000248A (es)
EA (1) EA012625B1 (es)
IL (1) IL183404A0 (es)
MA (1) MA29103B1 (es)
MX (1) MX2007006765A (es)
MY (1) MY144632A (es)
NO (1) NO20073033L (es)
NZ (1) NZ555406A (es)
PE (2) PE20110001A1 (es)
TW (1) TW200637836A (es)
UY (1) UY29249A1 (es)
WO (1) WO2006061258A2 (es)
ZA (1) ZA200704790B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2163256T3 (en) 2001-05-11 2015-12-07 Ludwig Inst For Cancer Res Ltd Specific binding proteins and use thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP5276017B2 (ja) * 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ変異体仲介性疾患の治療における抗ｅｇｆｒ抗体の使用
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
CN101688229B (zh) * 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
CN101851231A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种多西紫杉醇新衍生物的合成方法及其在制备抗肿瘤药物中的应用
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
ES2781523T3 (es) 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
CN104693156A (zh) * 2014-10-22 2015-06-10 上海大学 9,10-二羟基-1-去氧紫杉醇类似物及其制备方法
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
CN100522955C (zh) * 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途

Also Published As

Publication number Publication date
MA29103B1 (fr) 2007-12-03
ZA200704790B (en) 2008-08-27
WO2006061258A3 (en) 2006-09-28
EA012625B1 (ru) 2009-10-30
CA2588587A1 (en) 2006-06-15
DOP2005000248A (es) 2007-02-15
AU2005313444A1 (en) 2006-06-15
AU2005313444B2 (en) 2011-11-10
CN101094857A (zh) 2007-12-26
PE20110001A1 (es) 2011-01-21
EP1824858A2 (en) 2007-08-29
PE20061060A1 (es) 2006-11-14
AR054100A1 (es) 2007-06-06
IL183404A0 (en) 2007-10-31
EP1669358A1 (en) 2006-06-14
NZ555406A (en) 2011-02-25
MY144632A (en) 2011-10-14
US20060178427A1 (en) 2006-08-10
MX2007006765A (es) 2007-08-16
BRPI0518869A2 (pt) 2008-12-16
JP2008523019A (ja) 2008-07-03
KR20070085781A (ko) 2007-08-27
WO2006061258A2 (en) 2006-06-15
EA200701251A1 (ru) 2007-12-28
TW200637836A (en) 2006-11-01
US7667054B2 (en) 2010-02-23
UY29249A1 (es) 2006-06-30

Similar Documents

Publication Publication Date Title
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
TW200640893A (en) Cytotoxic agents comprising new C-2 modified taxanes
NO20066050L (no) Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav
ATE448777T1 (de) Mittel für die transdermale verabreichung von nikotin
NO20080068L (no) Topisk unguale formuleringer
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
CL2008001197A1 (es) Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras.
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA200700717A1 (ru) Сульфонамиды
NO20084712L (no) Nye farmasoytiske forbindelser
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200870019A1 (ru) Лактамовые соединения и способы их применения
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
ECSP077299A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
NO20090305L (no) Cyklosporin formuleringer
NO20084850L (no) MGLUR5 modulatorer I
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY28731A1 (es) Compuestos quimicos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application